2. GPCR/G Protein MAPK/ERK Pathway PI3K/Akt/mTOR Stem Cell/Wnt Protein Tyrosine Kinase/RTK
  3. Ras Akt ERK VEGFR
  4. NY0123

NY0123 is a EPAC1 inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT, phosphorylated ERK1/2 and phosphorylated VEGFR2. NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer. NY0123 is applicable to relevant research on triple-negative breast cancer.

For research use only. We do not sell to patients.

NY0123

NY0123 Chemical Structure

CAS No. : 1801911-70-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

NY0123 Related Antibodies

Top Publications Citing Use of Products

View All Ras Isoform Specific Products:

View All Isoforms
K-Ras H-Ras N-Ras Ras

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NY0123 is a EPAC1 inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT, phosphorylated ERK1/2 and phosphorylated VEGFR2. NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer. NY0123 is applicable to relevant research on triple-negative breast cancer[1].

IC50 & Target[1]

VEGFR2

 

ERK1

 

ERK2

 

EPAC1

 

In Vivo

NY0123 (10 mg/kg; i.p.; every two days; 14 days) significantly suppresses triple-negative breast cancer tumor growth, angiogenesis, and cell proliferation in BALB/c mice with greater efficacy than ESI-09 and no observed organ toxicity[1].
NY0123 (25-100 μM; topical application to CAM; single dose; 48-hour incubation) significantly suppresses angiogenesis in Gallus gallus domesticus embryo CAM models with greater efficacy than ESI-09[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 5-6 weeks old, 4T1 cell xenograft model)[1]
Dosage: 10 mg/kg
Administration: i.p.; every two days; 14 days
Result: Significantly reduced tumor volume and tumor weight compared to DMSO control.
Significantly lowered tumor microvessel density (measured via CD31 IHC staining) and tumor cell proliferation index (measured via Ki67 IHC staining) compared to DMSO control.
Exhibited greater inhibitory effects on tumor volume, tumor weight, MVD, and proliferation index than ESI-09.
Showed no treatment-related organ toxicities via H&E staining of heart, liver, lung, brain, spleen, kidney, and intestine tissues.
Animal Model: White leghorn (7-day-old embryo, CAM vascularization model)[1]
Dosage: 25 μM, 50 μM, 100 μM
Administration: topical application to CAM; single dose; 48-hour incubation
Result: Significantly reduced CAM microvessel density at 100 μM compared to DMSO control.
Exhibited greater inhibitory effects on angiogenesis at 100 μM than ESI-09 at the same concentration.
Molecular Weight

399.66

Formula

C16H13Cl3N4O2
CAS No.
SMILES

N#CC(=NNC1=CC(Cl)=C(Cl)C(Cl)=C1)C(=O)C2=NOC(=C2)C(C)(C)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

NY0123 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NY01231801911-70-5NY 0123NY-0123RasAktERKVEGFRPKBProtein kinase BExtracellular signal regulated kinasesVascular endothelial growth factor receptorangiogenic signaling networksPI3K/AKT pathwaysMEK/ERK pathwaysVEGF/VEGFR2 signalingtriple-negative breast cancervascular endothelial cellsBALB/c miceEPAC1Notch pathwaychick embryo CAM xenograft modelsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NY0123
Cat. No.:
HY-123795
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.